Skip to main content
HighTide Therapeutics, Inc. logo

HighTide Therapeutics, Inc. — Investor Relations & Filings

Ticker · 2511 HKEX Manufacturing
Open in API
Filings indexed 99 across all filing types
Latest filing 2026-01-02 Share Issue/Capital Cha…
Country HK Hong Kong
Listing HKEX 2511

About HighTide Therapeutics, Inc.

http://www.hightidetx.com

HighTide Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative, multifunctional, multi-targeted therapies. The company is dedicated to addressing unmet needs within the spectrum of inter-related chronic metabolic diseases, specifically emphasizing Cardiovascular-Kidney-Metabolic (CKM) conditions. HighTide's therapeutic strategy targets diseases driven by underlying mechanisms such as insulin resistance and chronic inflammation. The product pipeline includes five candidates covering nine indications in metabolic and digestive diseases. The lead candidate, HTD1801, is currently being advanced in chronic metabolic diseases, including MASH (Metabolic dysfunction-associated steatohepatitis), Type 2 Diabetes Mellitus (T2DM), Obesity, Primary Sclerosing Cholangitis (PSC), and Chronic Kidney Disease (CKD), utilizing its dual mechanism of action.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2025
Share Issue/Capital Change Classification · 1% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory requirement for listed companies to report monthly movements in their share capital, issued shares, and treasury shares. Since it details changes in capital structure and share issuance, it falls under the category of 'Share Issue/Capital Change'.
2026-01-02 English
TERMS OF REFERENCE FOR THE NOMINATION COMMITTEE
Governance Information Classification · 1% confidence The document is a formal 'Terms of Reference' for the Nomination Committee of HighTide Therapeutics, Inc. This type of document outlines the governance structure, committee responsibilities, and operational procedures of a board committee. It is a standard corporate governance document required for listed companies. Among the provided categories, 'Governance Information' (CGR) is the most accurate classification as it pertains to internal rules, board structure, and governance practices.
2025-12-24 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2025
Share Issue/Capital Change Classification · 1% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory requirement for listed companies to report monthly movements in their securities, including share capital and issued shares. Since it details changes in capital structure and share counts, it falls under the category of share issues and capital changes.
2025-12-02 English
HIGHTIDE THERAPEUTICS' HTD1801 ACHIEVES GREATER HBA1C REDUCTION AND SUPERIOR CARDIOMETABOLIC MARKER IMPROVEMENT VERSUS DAPAGLIFLOZIN IN PHASE III HEAD-TO-HEAD TRIAL
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement by HighTide Therapeutics regarding positive topline results from a Phase III clinical trial (HARMONY). It details the efficacy and safety data of their drug candidate HTD1801. Since this is a corporate announcement regarding business and clinical development rather than a formal financial report, dividend notice, or governance filing, it falls under the category of general regulatory announcements (RNS) as it is a standard disclosure to the Hong Kong Stock Exchange.
2025-12-02 English
LATE-BREAKING ASN 2025 | HIGHTIDE THERAPEUTICS PRESENTS EVIDENCE OF RENAL BENEFIT WITH HTD1801
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement by HighTide Therapeutics regarding the presentation of clinical trial data (HTD1801) at a medical conference (ASN 2025). It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a report publication announcement. As it is a general regulatory announcement regarding business/clinical development, it falls under the fallback category of Regulatory Filings (RNS).
2025-11-07 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2025
Share Issue/Capital Change Classification · 1% confidence The document is a Hong Kong Exchange (HKEX) monthly return (Form FF301) detailing movements in authorised share capital, issued shares, treasury shares, and confirmations under Chapter 19B. It is not an earnings release, annual report, or AGM material. It specifically reports changes and confirmations related to share capital and issuance. Therefore, it best fits the Share Issue/Capital Change category (SHA).
2025-11-04 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.